NASDAQ:SCYXSCYNEXIS Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SCYNEXIS Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.81 +0.04 (+5.19 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.77Now: $0.81▼$0.8650-Day Range$0.55MA: $0.86▼$1.1552-Week Range$0.50Now: $0.81▼$1.90Volume533,732 shsAverage Volume692,280 shsMarket Capitalization$78.91 millionP/E RatioN/ADividend YieldN/ABeta1.82 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.63, SCYNEXIS has a potential upside of 471.0% from its current price of $0.81.Amount of Analyst CoverageSCYNEXIS has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesSCYNEXIS has received 453 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSCYNEXIS has received 382 “underperform” votes. (Add your “underperform” vote.)Community SentimentSCYNEXIS has received 54.25% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote “Outperform” if you believe SCYX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.56% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions68.27% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for SCYNEXIS are expected to decrease by -47.62% in the coming year, from ($0.42) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 6.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SCYX Previous Symbol CUSIPN/A CIK1178253 Webhttp://www.scynexis.com/ Phone201-884-5485Debt Debt-to-Equity Ratio1.15 Current Ratio4.76 Quick Ratio4.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$120,000.00 Price / Sales657.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book6.23Profitability EPS (Most Recent Fiscal Year)($0.81) Net Income$-53,710,000.00 Net MarginsN/A Return on Equity-443.94% Return on Assets-102.19%Miscellaneous Employees24 Outstanding Shares97,420,000Market Cap$78.91 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive SCYX News and Ratings via Email Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SCYX Rates by TradingView SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions How has SCYNEXIS's stock been impacted by COVID-19 (Coronavirus)? SCYNEXIS's stock was trading at $0.7802 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SCYX stock has increased by 3.8% and is now trading at $0.81. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of SCYNEXIS? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SCYNEXIS. When is SCYNEXIS's next earnings date? SCYNEXIS is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for SCYNEXIS. How were SCYNEXIS's earnings last quarter? SCYNEXIS Inc (NASDAQ:SCYX) issued its quarterly earnings data on Wednesday, March, 11th. The company reported ($0.22) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.03. View SCYNEXIS's earnings history. What price target have analysts set for SCYX? 6 equities research analysts have issued 1-year price targets for SCYNEXIS's stock. Their forecasts range from $3.50 to $6.00. On average, they expect SCYNEXIS's stock price to reach $4.63 in the next year. This suggests a possible upside of 471.0% from the stock's current price. View analysts' price targets for SCYNEXIS. What are Wall Street analysts saying about SCYNEXIS stock? Here are some recent quotes from research analysts about SCYNEXIS stock: 1. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (3/18/2020) 2. Needham & Company LLC analysts commented, "Scynexis reported 1Q19 financial results this wk and we spoke w/ mgmt for an update. Enrollment in ibrexafungerp Phase 3 VANISH program in Acute Vulvovaginal Candidiasis (VVC) is progressing and mgmt reiterated guidance for top-line results in 1H20. Phase 3 CANDLE trial in Recurrent VVC is expected to start in 2Q19 (unch). Reiterate BUY. We believe commercial opportunity in VVC is substantially underappreciated by investors given there are no oral options for pts w/ poor response to standard of care oral fluconazole. Recent encouraging data from FURI and CARES trials demonstrating impressive activity against challenging infections (including tied to C. auris) enhances overall profile." (5/12/2019) Has SCYNEXIS been receiving favorable news coverage? News coverage about SCYX stock has trended very negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SCYNEXIS earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutSCYNEXIS. Who are some of SCYNEXIS's key competitors? Some companies that are related to SCYNEXIS include Axovant Sciences (AXON), Dynavax Technologies (DVAX), Beyondspring (BYSI), Syndax Pharmaceuticals (SNDX), NewLink Genetics (NLNK), Calithera Biosciences (CALA), Urovant Sciences (UROV), Satsuma Pharmaceuticals (STSA), DURECT (DRRX), Wave Life Sciences (WVE), Puma Biotechnology (PBYI), Avadel Pharmaceuticals (AVDL), TherapeuticsMD (TXMD), Lannett (LCI) and MacroGenics (MGNX). What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Cerus (CERS), Novavax (NVAX), Viking Therapeutics (VKTX), Nabriva Therapeutics (NBRV), Verastem (VSTM), Micron Technology (MU), Trevena (TRVN), Agile Therapeutics (AGRX), Advanced Micro Devices (AMD) and Synergy Pharmaceuticals (SGYP). Who are SCYNEXIS's key executives? SCYNEXIS's management team includes the following people: Marco Taglietti, President, Chief Executive Officer & DirectorEric Francois, Chief Financial OfficerDavid Angulo Gonzalez, Chief Medical OfficerRajeshwar Motheram, Vice President-Pharmaceutical DevelopmentScott Sukenick, General Counsel What is SCYNEXIS's stock symbol? SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX." How do I buy shares of SCYNEXIS? Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is SCYNEXIS's stock price today? One share of SCYX stock can currently be purchased for approximately $0.81. How big of a company is SCYNEXIS? SCYNEXIS has a market capitalization of $78.91 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. SCYNEXIS employs 24 workers across the globe. View additional information about SCYNEXIS. What is SCYNEXIS's official website? The official website for SCYNEXIS is http://www.scynexis.com/. How can I contact SCYNEXIS? SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: What is the Shanghai Stock Exchange Composite Index?
